Life Cycle Management in the Pharmaceutical Industry Using an Applicable and Robust LCA-Based Environmental Sustainability Assessment Approach

Abstract

Despite growing concerns over the environmental impacts of pharmaceuticals, the use of Life Cycle Assessment (LCA) within the pharma-sector remains quite fragmentary. The aim of this paper is to present gaps and challenges, impeding a full adoption of LCA in the pharma-sector. A review of existing pharma-LCAs revealed a considerable degree of inconsistency and inhomogeneity in their methodological choices, highlighting the need for product category rules (PCRs) for the pharmaceutical industry to harmonize and facilitate the future use of LCA in that sector. Additionally, existing life cycle impact assessment (LCIA) methods fail to model several pharma-specific impact pathways (e.g. endocrine disruption). Preliminary thoughts on the development of pharma-PCRs and the inclusion of pharma-specific impact pathways into LCIA are presented, providing important stimulus for further research.